These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 37435963)
1. Rheumatic complications of checkpoint inhibitors: Lessons from autoimmunity. Reynolds G Immunol Rev; 2023 Sep; 318(1):51-60. PubMed ID: 37435963 [TBL] [Abstract][Full Text] [Related]
2. Treatment of rheumatic adverse events of cancer immunotherapy. Reid P; Cappelli LC Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321 [TBL] [Abstract][Full Text] [Related]
3. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Ohnuma K; Hatano R; Dang NH; Morimoto C Mod Rheumatol; 2019 Sep; 29(5):721-732. PubMed ID: 30285531 [TBL] [Abstract][Full Text] [Related]
4. [Rheumatological complications of immune checkpoint inhibitor therapy]. Lazarou I; Fernandez E Rev Med Suisse; 2020 Mar; 16(685):504-507. PubMed ID: 32167253 [TBL] [Abstract][Full Text] [Related]
5. Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors. Cano-Cruz LG; Barrera-Vargas A; Mateos-Soria A; Soto-Perez-de-Celis E; Merayo-Chalico J Arch Med Res; 2022 Feb; 53(2):113-121. PubMed ID: 34649738 [TBL] [Abstract][Full Text] [Related]
6. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. Leipe J; Mariette X Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078 [TBL] [Abstract][Full Text] [Related]
7. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology. Cappelli LC; Shah AA; Bingham CO Rheum Dis Clin North Am; 2017 Feb; 43(1):65-78. PubMed ID: 27890174 [TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know? Gediz F; Kobak S Curr Rheumatol Rev; 2019; 15(3):201-208. PubMed ID: 30659547 [TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. Thanarajasingam U; Abdel-Wahab N Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606 [TBL] [Abstract][Full Text] [Related]
10. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy. Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042 [TBL] [Abstract][Full Text] [Related]
11. [Clinical management of rheumatic immune-related adverse events : Recognize and treat rheumatological side effects of checkpoint inhibition]. Benesova K; Leipe J Z Rheumatol; 2020 Aug; 79(6):545-553. PubMed ID: 32613268 [TBL] [Abstract][Full Text] [Related]
12. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. Mitchell EL; Lau PKH; Khoo C; Liew D; Leung J; Liu B; Rischin A; Frauman AG; Kee D; Smith K; Brady B; Rischin D; Gibson A; Mileshkin L; Klein O; Weickhardt A; Arulananda S; Shackleton M; McArthur G; Östör A; Cebon J; Solomon B; Buchanan RR; Wicks IP; Lo S; Hicks RJ; Sandhu S Eur J Cancer; 2018 Dec; 105():88-102. PubMed ID: 30439628 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Kostine M; Truchetet ME; Schaeverbeke T Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082 [TBL] [Abstract][Full Text] [Related]
14. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. Richter MD; Pinkston O; Kottschade LA; Finnes HD; Markovic SN; Thanarajasingam U Arthritis Rheumatol; 2018 Mar; 70(3):356-360. PubMed ID: 29363290 [TBL] [Abstract][Full Text] [Related]
16. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Abdel-Wahab N; Suarez-Almazor ME Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084 [TBL] [Abstract][Full Text] [Related]
18. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Kostine M; Finckh A; Bingham CO; Visser K; Leipe J; Schulze-Koops H; Choy EH; Benesova K; Radstake TRDJ; Cope AP; Lambotte O; Gottenberg JE; Allenbach Y; Visser M; Rusthoven C; Thomasen L; Jamal S; Marabelle A; Larkin J; Haanen JBAG; Calabrese LH; Mariette X; Schaeverbeke T Ann Rheum Dis; 2021 Jan; 80(1):36-48. PubMed ID: 32327425 [TBL] [Abstract][Full Text] [Related]
19. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. Lee KA; Kim HR; Yoon SY Korean J Intern Med; 2019 Nov; 34(6):1197-1209. PubMed ID: 31014065 [TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists. Pacholczak-Madej R; Kosałka-Węgiel J; Kuszmiersz P; Mituś JW; Püsküllüoğlu M; Grela-Wojewoda A; Korkosz M; Bazan-Socha S Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36981837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]